Stock Financial Ratios, Dividends, Split History
CCMP / Cabot Microelectronics Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||2,898.54|
|Enterprise Value ($M)||2,606.96|
|Book Value ($M)||635.51|
|Book Value / Share||24.74|
|Price / Book||4.56|
|NCAV / Share||14.32|
|Price / NCAV||7.97|
|Common Shares Outstanding||25,356,916|
|Common Stock Shares Outstanding||35,230,742|
|Weighted Average Number Of Shares Outstanding Basic||25,015,458|
|Weighted Average Number Of Diluted Shares Outstanding||25,512,487|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||0.12|
|Return on Assets (ROA)||0.12|
|Return on Equity (ROE)||0.17|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1102934|
|12709P903 012709P10 12709P953|
|SIC 3674 - Semiconductors and Related Devices|
Stock splits are used by Cabot Microelectronics Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
9h - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
2018-07-13 - Asif
Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...
2018-07-09 - Asif
Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...
Related News Stories
New orders for major U.S.-made capital goods improved more than expected in April, as per Friday’s Commerce Department data. A decent rebound in business equipment orders placed with factories indicated resilient demand at the start of the second quarter. Philly Fed factory orders also touched a 45-year high in May. The pace of economic boom is levelling out in the United States and by no means signals a downturn. (18-0)
It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach. (11-1)
Synchronoss Technologies, Inc. (SNCR - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down 45% in the past one-month time frame. (31-1)
Investors in TransEnterix, Inc. (TRXC - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the May 18, 2018 $2 Call had some of the highest implied volatility of all equity options today. (71-5)
as of ET